CLAIMS

1. A compound having Structural Formula S4-14:



S4-14,

or a pharmaceutically acceptable salt thereof, wherein:

R^4 is -(C_1-C_6 alkyl); and

$R^{4'}$ is -(C_2-C_6 alkyl).

2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of Claim 1.

3. A compound of Claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 2, for use in the treatment of bacterial infection.

4. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by an organism that grows intracellularly as part of its infection process.

5. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by a Gram-positive organism.

6. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the Gram-positive organism is selected from the class Bacilli; phylum Actinobacteria; and class Clostridia.

7. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 6, wherein the class Bacilli organism is selected from *Staphylococcus* spp., *Streptococcus* spp., *Enterococcus* spp., *Bacillus* spp., and *Listeria* spp.

8. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 6, wherein the class phylum Actinobacteria organism is selected from *Propionibacterium* spp., *Corynebacterium* spp., *Nocardia* spp., and *Actinobacteria* spp.

9. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 6, wherein the class Clostridia organism is selected from *Clostridium* spp.

10. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by a Gram-negative organism.

11. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the Gram-negative organism is selected from the group consisting of *Enterobactericeae, Bacteroidetes, Vibrionaceae, Pasteurellaceae, Pseudomonadaceae, Neisseriaceae, Rickettsiae, Moraxellaceae* any species of *Proteeae, Acinetobacter* spp., *Helicobacter* spp., and *Campylobacter* spp.

12. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by an organism selected from order Rickettsiales and order Chlamydiales.

13. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by an organism selected from the phylum Chlamydiae and phylum Spriochaetales.

14. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 13, wherein the phylum Spriochaetales organism is selected from *Borrelia* spp. and *Treponema* spp.

15. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by an organism selected from the class Mollicutes.

16. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 15, wherein the class Mollicutes organism is selected from *Mycoplasma* spp.

17. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 16, wherein *Mycoplasma* spp. is *Mycoplasma pneumoniae.*

18. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by an organism selected from *Legionella* spp. and *Mycobacterium* spp.

19. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 18, wherein the *Mycobacterium* spp is *Mycobacterium tuberculosis.*

20. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by more than one organism.

21. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by an organism resistant to one or more antibiotics.

22. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by an organism resistant to tetracycline or any member of first and second generation of tetracycline antibiotics.

23. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by an organism resistant to methicillin or any antibiotic in the β-lactam class.

24. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 23, wherein the β-lactam class is selected from second, third and fourth-generation cephalosporins.

25. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by an organism resistant to a quinolone or fluoroquinolone.

26. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by an organism resistant to tigecycline.

27. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by an organism resistant to tetracycline.

28. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by an organism resistant to methicillin.

29. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by an organism resistant to vancomycin.

30. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 3, wherein the infection is caused by an organism resistant to an antimicrobial peptide or a biosimilar therapeutic treatment.

31. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the Gram-positive organism is selected from *S. aureus,* CoNS, *S. pneumoniae*, *S. pyogenes, S. agalactiae*, *E. faecalis* and *E. faecium*.

32. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the Gram-negative organism is selected from selected from *H. influenza, M. catarrhalis* and *Legionella pneumophila*.

33. A compound of Claim 1, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 2 for use in the treatment of a respiratory infection caused by bacteria.

34. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 33, wherein the respiratory infection is Community-Acquired Bacterial Pneumonia (CABP).

35. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 33 or Claim 34, wherein the respiratory infection is caused by a bacterium selected from *S. aureus, S. pneumoniae*, *S. pyogenes*, *H. influenza, M. catarrhalis* and *Legionella pneumophila.*

36. A compound of Claim 1, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 2 for use in the treatment of a skin infection caused by bacteria.

37. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 36, wherein the skin infection is an acute bacterial skin and skin structure infection (ABSSSI).

38. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 36 or Claim 37, wherein the skin infection is caused by a bacterium selected from *S. aureus*, CoNS, *S. pyogenes*, *S. agalactiae*, *E. faecalis* and *E. faecium*.

39. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition, as claimed in Claim 10, wherein the Gram-negative organism is *A. baumanii*.